www.medical-devices.tech
16
'26
Written on Modified on
Solid Dosage Formulation Scale-Up via Tabletop Laboratory Granulation Systems
Syntegon is expanding its North American pharmaceutical development capabilities by presenting the Mycromix and Solidlab 1 systems at PharmSci 360.
www.syntegon.com
Stock Image
Active pharmaceutical ingredient development frequently encounters critical scale-up discrepancies when transitioning early formulations from laboratory feasibility trials to industrial oral solid dosage manufacturing lines. To bridge these hydrodynamic and thermal disparities, Syntegon is presenting its small-scale research and development portfolio, featuring the Mycromix high-shear mixer and the Solidlab 1 multi-process system, at the American Association of Pharmaceutical Scientists PharmSci 360 event.
Operational Scale-Up Barriers in Oral Solid Dosage Formulation
During the formulation stages of oral solid dosage forms, pharmaceutical scientists face strict active pharmaceutical ingredient supply constraints, often limiting early-stage trial material to batches under one kilogram. Formulators must evaluate critical process parameters—including wet massing kinetics, binder distribution, fluidization drying rates, and film coating thickness—using tabletop systems.
A persistent engineering obstacle in early-stage formulation is the geometric and mechanical dissimilarity between benchtop equipment and commercial production machinery. When laboratory mixers utilize different impeller profiles, vessel aspect ratios, or shear mechanics than commercial granulators, critical operational data such as binder spray rates, tip speeds, and wet granule densification cannot be mathematically scaled. This lack of process correlation leads to extended scale-up timelines, out-of-specification granule size distributions, and tableting failures during subsequent technology transfers to pilot and commercial sites.
Engineering Kinematics of the Mycromix High-Shear Granulator
The Mycromix tabletop unit resolves geometric transfer issues by utilizing identical process kinematics to Syntegon commercial high-shear granulators. The system operates with interchangeable product bowls spanning capacities from 0.5 to 10 liters, enabling researchers to conduct formulation trials on limited active ingredient masses.
Mechanical mixing is driven by Syntegon Gentlewing impeller technology paired with a high-speed vertical chopper. Because the impeller blade geometry and chopper orientation match the operational configuration of pilot and commercial production mixers, the fluid dynamic flow patterns—specifically the toroidal powder bed motion—remain geometrically aligned across scales. This mechanical continuity allows engineers to correlate impeller tip speed, Froude number calculations, and motor torque consumption directly to commercial granulation endpoints. The unit provides modular configurations, including jacketing for thermal control via circulating heating or cooling media, specialized preparations for hazardous organic solvent handling, and optional three-blade impeller profiles.
Modular Fluidized Bed and Coating Mechanics in Solidlab 1
Feasibility studies covering downstream agglomeration, drying, and tablet finishing are executed on the Solidlab 1 tabletop unit. The platform consolidates multiple unit operations onto a single machine frame by accommodating either a fluidized bed chamber or a perforated drum coating module:
Active pharmaceutical ingredient development frequently encounters critical scale-up discrepancies when transitioning early formulations from laboratory feasibility trials to industrial oral solid dosage manufacturing lines. To bridge these hydrodynamic and thermal disparities, Syntegon is presenting its small-scale research and development portfolio, featuring the Mycromix high-shear mixer and the Solidlab 1 multi-process system, at the American Association of Pharmaceutical Scientists PharmSci 360 event.
Operational Scale-Up Barriers in Oral Solid Dosage Formulation
During the formulation stages of oral solid dosage forms, pharmaceutical scientists face strict active pharmaceutical ingredient supply constraints, often limiting early-stage trial material to batches under one kilogram. Formulators must evaluate critical process parameters—including wet massing kinetics, binder distribution, fluidization drying rates, and film coating thickness—using tabletop systems.
A persistent engineering obstacle in early-stage formulation is the geometric and mechanical dissimilarity between benchtop equipment and commercial production machinery. When laboratory mixers utilize different impeller profiles, vessel aspect ratios, or shear mechanics than commercial granulators, critical operational data such as binder spray rates, tip speeds, and wet granule densification cannot be mathematically scaled. This lack of process correlation leads to extended scale-up timelines, out-of-specification granule size distributions, and tableting failures during subsequent technology transfers to pilot and commercial sites.
Engineering Kinematics of the Mycromix High-Shear Granulator
The Mycromix tabletop unit resolves geometric transfer issues by utilizing identical process kinematics to Syntegon commercial high-shear granulators. The system operates with interchangeable product bowls spanning capacities from 0.5 to 10 liters, enabling researchers to conduct formulation trials on limited active ingredient masses.
Mechanical mixing is driven by Syntegon Gentlewing impeller technology paired with a high-speed vertical chopper. Because the impeller blade geometry and chopper orientation match the operational configuration of pilot and commercial production mixers, the fluid dynamic flow patterns—specifically the toroidal powder bed motion—remain geometrically aligned across scales. This mechanical continuity allows engineers to correlate impeller tip speed, Froude number calculations, and motor torque consumption directly to commercial granulation endpoints. The unit provides modular configurations, including jacketing for thermal control via circulating heating or cooling media, specialized preparations for hazardous organic solvent handling, and optional three-blade impeller profiles.
Modular Fluidized Bed and Coating Mechanics in Solidlab 1
Feasibility studies covering downstream agglomeration, drying, and tablet finishing are executed on the Solidlab 1 tabletop unit. The platform consolidates multiple unit operations onto a single machine frame by accommodating either a fluidized bed chamber or a perforated drum coating module:
- Fluidized Bed Module: Accommodates two distinct container geometries capable of processing batch loads ranging from 0.05 to 1 kilogram. The assembly supports top-spray granulation, bottom-spray Wurster coating, and convective drying.
- Perforated Drum Coater: Utilizes two exchangeable drum geometries engineered for tablet batches between 0.25 and 1.2 kilograms. Process air conditioning and suspension delivery parameters mirror larger production-scale tablet coaters.
Process management across both modules is controlled by the PROVICON operating software. The architecture provides an open recipe programming environment that allows researchers to parameterize air volume, inlet air dew point, liquid feed rate, and atomization pressures. Recipe structures and process logs created in the software environment facilitate direct data transfer to commercial supervisory control and data acquisition systems.
North American Technical Deployment and Industry Showcase
Syntegon is exhibiting these technologies at the American Association of Pharmaceutical Scientists PharmSci 360 conference, scheduled for October 25 to 28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Alongside hardware exhibitions, the company provides local application engineering support via regional oral solid dosage Academy workshops, giving formulation scientists access to pilot testing facilities to establish robust design spaces prior to clinical manufacturing.
Additional Context:
This section details technical specifications and competitive benchmarking not included in the original product announcement.
Laboratory-scale oral solid dosage development equipment relies on strict dimensional scaling laws, particularly regarding impeller tip speed (typically 5 to 10 m/s in high-shear wet granulation) and volumetric air-to-cloth ratios in fluidized bed systems. Within the high-shear benchtop segment, the Syntegon Mycromix directly competes with modular systems such as the GEA PharmaConnect (incorporating PMA and Gral process vessels from 1 to 10 liters) and the Glatt VG series. While competitors often employ proprietary automated endpoint detection based on motor power curves or acoustic sensors, Syntegon emphasizes direct geometric translation via its specific Gentlewing blade profile across both laboratory and bulk production capacities.
In multi-functional processing units, the Solidlab 1 competes with benchtop systems such as the Glatt Mini-Glatt and the Freund-Vector VFC-Lab series. Multi-functional R&D processors generally range in batch capacity from 0.05 to 2.5 kg. A primary engineering distinction in the Solidlab 1 architecture is the integration of shared process air handling and control systems across distinct unit operations—fluidized bed drying and pan coating—utilizing a common PROVICON control architecture to reduce laboratory footprint requirements.
Edited by Natania Lyngdoh, Induportals editor, with AI assistance.
www.syntegon.com
